Partners

With COUR’s expertise in inflammatory diseases, Takeda is well positioned to further develop TAK-101 in pursuit of providing the first approved treatment option for patients with celiac disease, a multi-billion dollar market

COUR’s expertise in immune reprogramming coupled with Ironwood’s commercial strength and reach in GI position CNP-104 to be the first PBC product that treats the underlying drivers of disease instead of treating symptoms